India, June 8 -- Vor Bio (VOR) today announced that Telitacicept (developed by RemeGen) has received approval from China's NMPA for the treatment of adult patients with Sjogren's disease.
Sjogren's disease (SjD), a chronic autoimmune condition that affects moisture-producing glands and can cause dry eyes, dry mouth, fatigue, and systemic complications. This marks the first and only approved therapy for SjD in China.
Telitacicept is a novel fusion protein that simultaneously targets B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), two pathways implicated in autoimmune disease progression. By modulating abnormal B-cell activity, the therapy aims to reduce systemic inflammation and improve patient symptoms across ...